Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
- Conditions
- Hematological Malignancies
- Interventions
- Biological: G-CSFRadiation: Total lymphoid irradiationBiological: Lymphocyte infusionsDevice: CliniMACS
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02199041
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
- Conditions
- Lymphoma (Hodgkin's and Non-Hodgkin's)Acute Myelogenous Leukemia (AML)Chronic Myeloid Leukemia (CML)Myelodysplastic Syndrome (MDS)Juvenile Myelomonocytic Leukemia (JMML)Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Device: CliniMACS CD34+ Reagent System
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Diane George
- Target Recruit Count
- 14
- Registration Number
- NCT02061800
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Istituto Clinico Humanitas
- Target Recruit Count
- 47
- Registration Number
- NCT02049580
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, MI, Italy
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
- Conditions
- High-risk Medulloblastoma
- Interventions
- Drug: Temozolimide + IrinotecanCombination Product: Etoposide + radiotherapy
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 29
- Registration Number
- NCT02025881
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷Centre Oscar Lambret, Lille, France
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Conditions
- Primary Immunodeficiency (PID)Inherited Metabolic Disorders (IMD)Congenital Bone Marrow Failure SyndromesHereditary AnemiasJuvenile Rheumatoid Arthritis (JRA)Inflammatory ConditionsSystemic Juvenile Idiopathic Arthritis (sJIA)
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 100
- Registration Number
- NCT01962415
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
- Conditions
- Acute Lymphoblastic Leukaemia
- Interventions
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- St. Anna Kinderkrebsforschung
- Target Recruit Count
- 1800
- Registration Number
- NCT01949129
- Locations
- 🇦🇷
Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit, La Plata, Argentina
🇧🇪University Hospitals Leuven Kinderhemato-oncologie, Leuven, Belgium
🇮🇱Dana Children's Hospital, Tel Aviv, Israel
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Adult Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous LineageAdult Acute Myeloid Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationBiological: T Cell-Depleted Hematopoietic Stem Cell TransplantationRadiation: Total-Body Irradiation
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01858740
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
T&B Depletion Non Malignant
- Conditions
- Graft Versus Host Disease
- Interventions
- Biological: polyclonal antibody
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Franco Locatelli
- Target Recruit Count
- 130
- Registration Number
- NCT01810926
- Locations
- 🇮🇹
San Raffaele Scientific Institute, Milano, Italy
🇮🇹University of Cagliari, Cagliari, Italy
🇮🇹University of Milano-Bicocca San Gerardo Hospital, Monza, Italy
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
- Conditions
- LeukemiaLymphoma
- Interventions
- Radiation: Total Lymphoid IrradiationBiological: HPC,A InfusionBiological: TC-NK InfusionBiological: G-CSFDevice: CliniMACS
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT01807611
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas
- Conditions
- B-cell Lymphoma Refractory
- Interventions
- Drug: FludarabinProcedure: transplant (HCT)Radiation: CytoreductionDrug: ImmunosuppressionProcedure: Collection and infusions of Donor PBSC
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Azienda Ospedaliera San Giovanni Battista
- Target Recruit Count
- 42
- Registration Number
- NCT01786018
- Locations
- 🇮🇹
Città della Salute e della Scienza di Torino, Torino, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.